Dr Bestvina on the Management of AEs Associated With Repotrectinib in ROS1+ NSCLC
Christine Bestvina, MD, discusses strategies for managing adverse effects associated with the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.
Source: onclive.com